Latest News and Press Releases

Idag har en överenskommelse nåtts mellan Oasmia och dess största ägare Arwidsro. Den handlar dels om att lösa upp tidigare oklarheter, dels om att tillföra Oasmia kapital för att fortsätta satsningen...

Today an agreement has been made between Oasmia and its largest shareholder Arwidsro. The agreement is made to solve earlier unclear balances and to support the planned commercialization of Oasmia...

Oasmia tillsätter Business Advisory Board med målsättningen att främst ge stöd åt kommersialiseringen av Apealea samt utvärdera vilka utvecklings- och marknadsmöjligheter som finns för de övriga...

Oasmia has appointed a Business Advisory Board with the aim of primarily supporting the commercialization of Apealea and evaluating development and market opportunities for the other product...

Oasmia tillkännager idag bildandet av sitt Scientific Advisory Board med tre viktiga utnämningar: Professor Rolf Lewensohn, MD, PhD, Hans Grönlund, PhD and Ola Winqvist, MD, PhD. Scentific...

Oasmia today announces the formation of its Scientific Advisory Board with three key appointments: Professor Rolf Lewensohn, MD, PhD, Hans Grönlund, PhD and Ola Winqvist, MD, PhD. The scientific...

Nina Heldring, PhD, har idag utsetts till tf CMO (Chief Medical Officer) för Oasmia Pharmaceutical AB. Nina Heldring har 20 års erfarenhet av preklinisk och klinisk medicinsk forskning från kända...

Nina Heldring, PhD, has today been appointed as acting CMO of Oasmia Pharmaceutical AB. Nina Heldring has 20 years of experience with pre-clinical and clinical medical research from renowned...

The Board of Oasmia has decided to report certain suspicious transactions that has been made by the company during several years to the Swedish Economic Crime Authority. In connection with a tax...

Sven Rohmann, MD PhD MBA, has today been appointed as acting CEO of Oasmia Pharmaceutical AB. He assumes his new role July 1, 2019. Since March 2019 Sven Rohmann has been a member of the Board of...